Areef Ishani, Allan J. Collins, Charles A. Herzog, Robert N. Foley

Slides:

Advertisements

Similar presentations

Chapter 2: Identification and Care of Patients With CKD 2014 ANNUAL DATA REPORT VOLUME 1: CHRONIC KIDNEY DISEASE.

Advertisements

Chapter 5: Mortality 2014 A NNUAL D ATA R EPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE.

2016 Annual Data Report, Vol 2, ESRD, Ch 5

2016 Annual Data Report, Vol 2, ESRD, Ch 6

Optimization of pre-ESRD care: The key to improved dialysis outcomes

Patient populations by study group figure 10

Copyright © 2007 American Medical Association. All rights reserved.

Masaya Koshizaka, MD, PhD, Renato D. Lopes, MD, PhD, MHS, L

Brian Radbill, MD, Barbara Murphy, MD, Derek LeRoith, MD, PhD

Chapter 2: Pharmacological cholesterol-lowering treatment in adults

Health care utilization among patients with chronic kidney disease

Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure Steven Fishbane, Nobuyuki Miyawaki Kidney International

Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients G.A. Block, P. Raggi, A. Bellasi, L. Kooienga,

The US Renal Data System “Pie Chart of Death”

Survival differences between peritoneal dialysis and hemodialysis among “large” ESRD patients in the United States Austin G. Stack, Bhamidipati V.R.

Volume 57, Issue 5, Pages (May 2000)

Mortality caused by sepsis in patients with end-stage renal disease compared with the general population Mark J. Sarnak, Bertrand L. Jaber Kidney International

Volume 64, Issue 3, Pages (September 2003)

Shikhar Agarwal, MD, MPH, Aatish Garg, MD, Akhil Parashar, MD, Lars G

Type of vascular access and mortality in U.S. hemodialysis patients

Smoking and cardiovascular outcomes in dialysis patients: The United States Renal Data System Wave 2 Study1,2 Robert N. Foley, Charles A. Herzog, Allan.

Effects of statin therapy on cerebrovascular and renal outcomes in patients with predialysis advanced chronic kidney disease and dyslipidemia Chang-Min.

Tetsuro Tsujimoto, Hiroshi Kajio International Journal of Cardiology

Volume 79, Pages S9-S13 (April 2011)

Blood Pressure and Outcomes in Very Old Hypertensive Coronary Artery Disease Patients: An INVEST Substudy Scott J. Denardo, MD, Yan Gong, PhD, Wilmer.

Volume 69, Pages S11-S15 (April 2006)

Figure 1 Diagram showing analysis flow of patient selection and treatment allocation of ONTARGET/TRANSCEND. Figure 1 Diagram showing analysis flow of patient.

Volume 81, Issue 3, Pages (February 2012)

Vitality Measured as Self-reported Energy Level and Clinical Outcomes in Hemodialysis Patients: The Japanese Dialysis Outcomes and Practice Pattern Study.

Homocysteine and risk in end-stage renal disease: a matter of context

Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease Johannes F.E. Mann, Qi-Long.

C.Y. Hsu, J.D. Ordoñez, G.M. Chertow, D. Fan, C.E. McCulloch, A.S. Go

Volume 76, Issue 10, Pages (November 2009)

Acute myocardial infarction in patients with chronic kidney disease: how are the most vulnerable patients doing? Gautam R. Shroff, Charles A. Herzog

Management of Heart Failure in Advancing CKD: Core Curriculum 2018

Survival advantage in Asian American end-stage renal disease patients1

Volume 68, Issue 5, Pages (November 2005)

On Statin Treatment to Prevent Sepsis in Dialysis Patients

Patient selection affects end-stage renal disease outcome comparisons

Volume 77, Issue 7, Pages (April 2010)

Volume 77, Issue 2, Pages (January 2010)

Jennifer E. Flythe, Stephen E. Kimmel, Steven M. Brunelli

U-shaped effect of eGFR and mortality

Acute myocardial infarction in patients with end-stage renal disease

Volume 83, Issue 4, Pages (April 2013)

Amit X. Garg, William F. Clark, R. Brian Haynes, Andrew A. House

Cardiac medications and their association with cardiovascular events in incident dialysis patients: Cause or effect? Areef Ishani, Charles A. Herzog,

Volume 83, Issue 2, Pages (February 2013)

Trends and Outcomes Associated With Serum Albumin Concentration Among Incident Dialysis Patients in the United States George A. Kaysen, MD, PhD, Kirsten.

Cardiovascular disease in pediatric chronic dialysis patients

Counteracting progression of renal disease: A look into the future

Volume 80, Issue 6, Pages (September 2011)

Lynda Anne Szczech, Ira L. Lazar Kidney International

Volume 58, Issue 1, Pages (July 2000)

Volume 67, Issue 5, Pages (May 2005)

Volume 72, Issue 4, Pages (August 2007)

Volume 80, Issue 12, Pages (December 2011)

Volume 82, Issue 3, Pages (August 2012)

Volume 57, Issue 4, Pages (April 2000)

Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study1 Robert N. Foley, Charles A. Herzog, Allan J.

Volume 61, Issue 2, Pages (February 2002)

Long-term outcome of dialysis patients in the United States with coronary revascularization procedures Charles A. Herzog, M.D., Jennie Z. Ma, Allan J.

Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension Julian Segura, Carlos Campo, Luis M. Ruilope Kidney.

Volume 68, Issue 1, Pages (July 2005)

Charles A. Herzog Kidney International

Volume 75, Issue 1, Pages (January 2009)

Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes Steven M. Brunelli, Ravi Thadhani,

Volume 61, Issue 2, Pages (February 2002)

Optimization of pre-ESRD care: The key to improved dialysis outcomes

Identification of thresholds for significant renal recovery in relation to patient and renal survival. Identification of thresholds for significant renal.

Presentation transcript:

Septicemia, access and cardiovascular disease in dialysis patients: The USRDS Wave 2 Study1 Areef Ishani, Allan J. Collins, Charles A. Herzog, Robert N. Foley Kidney International Volume 68, Issue 1, Pages 311-318 (July 2005) DOI: 10.1111/j.1523-1755.2005.00414.x Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 1 Cumulative incidence of bacteremia or septicemia over time in the Wave 2 population. Kidney International 2005 68, 311-318DOI: (10.1111/j.1523-1755.2005.00414.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 2 Actuarial adjusted survival estimates after a diagnosis of bacteremia, septicemia, either septicemia or bacteremia and myocardial infarction in the Wave 2 population. Adjusted for the following variables: history of myocardial infarction, congestive heart failure, cerebrovascular accident, peripheral vascular disease, and diabetes, primary cause of kidney disease (diabetes, hypertension, glomerulonephritis, other), age, race (black, white, other), mean predialysis systolic and diastolic blood pressure, and an albumin <3.0 mg/dL). Kidney International 2005 68, 311-318DOI: (10.1111/j.1523-1755.2005.00414.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 3 Hazards ratios for death, hospitalized congestive heart failure (CHF), myocardial infarction (MI), peripheral vascular disease (PVD) and cerebrovascular accident (CVA). The results are reported for the occurrence of bacteremia or septicemia (b or s), bacteremia alone (b), or septicemia alone (s). In each model the outcome of interest was modeled as a time-dependent covariate, with adjustment for baseline dialysis access, comorbidities, primary renal disease, age, race, gender, systolic blood pressure, diastolic blood pressure, and serum albumin. Kidney International 2005 68, 311-318DOI: (10.1111/j.1523-1755.2005.00414.x) Copyright © 2005 International Society of Nephrology Terms and Conditions